

Supplementary Information

X. Hu, U. Khatri, T. Shen, and J. Wu. Progress and challenges in RET-targeted cancer therapy

Table S1. RET fusion partners identified in human cancer

Fusion partner	Cancer type	Cancer type abbreviation:
ACBD5	PTC	AML, acute myeloid leukemia
ADD3	NSCLC	AS, lung adenosquamous cell carcinoma;
AFAP1L2	PTC	BRCA, breast invasive carcinoma;
AFF2	LADC	CMML, Chronic myelomonocytic leukemia;
AKAP13	PTC, NSCLC	CRC, colorectal carcinoma;
ANK3	NSCLC	IC, intraductal carcinoma of the salivary gland;
ANKRD26	PTC, NSCLC	IFS, infantile fibrosarcoma;
ANKS1B	NSCLC	IM, infantile myofibromatosis;
ARHGAP12	NSCLC	IMA, invasive mucinous lung adenocarcinoma;
BCR	CMML	IMT, Inflammatory myofibroblastic tumor of soft tissues;
C10orf11	NSCLC	LADC, lung adenocarcinoma;
c7orf61	NSCLC	LPF, lipofibromatosis;
CCDC186	NSCLC	LPF-NT, lipofibromatosis-like neuronal tumors;
CCDC3	NSCLC	MTC, medullary thyroid carcinoma;
CCDC6	PTC, PDTC, LADC, BRCA, SCT, CRC, STAD, OVA, STAD	NSCLC, non-small cell lung cancer
CCDC88C	NSCLC	OVA, ovarian cancer
CCNYL2	NSCLC	PDTC, poorly differentiated thyroid carcinoma;
CDH23	NSCLC	PMF, primary myelofibrosis;
CGNL1	NR	PTC, papillary thyroid carcinoma;
CLIP1	NSCLC	PSCN, pigmented spindle cell nevus of Reed;
CLIP2	LADC	SC, secretory carcinoma of the salivary gland;
CLRN3	PTC	SCT, spindle cell tumor of soft tissues;
CTNNA3	NSCLC	SN, spitzoid neoplasms;
CUBN	LADC	STAD, stomach adenocarcinoma;
CUX1	NSCLC	STC, soft tissue carcinoma;
DLG5	PTC	
DOCK1	NSCLC	
DYDC1	NSCLC	
EDC4	NSCLC	
EML4	NSCLC	
EML6	NSCLC	
EPC1	NSCLC	
EPHA5	LADC	
ERC1	NSCLC, PTC, BRCA	
ETV6	SC	
FGFR1OP	CMML, PMF	
FKBP15	PTC, AML	
FRMD4A	LADC	
FRMD4A(KIAA1294)	LADC	
FXYD4	NSCLC	
GOLGA5	PTC, SN	
GPHN	NR	
GPR139	NSCLC	
GPRC5B	NSCLC	
HOOK3	PTC	
IGR	NSCLC	
JMJD1C	NR	
KIAA1217	NSCLC	
KIAA1468/RELCH	NSCLC, IMA, PTC	
KIF13A	LADC	
KIF5B	LADC, AS, SN	
KTN1	PTC	
LMNA	NSCLC	
LSM14A	NSCLC	
MPRIIP	NSCLC	
MRLN	PTC	
MYH10	IM, SCT	
MYH13	MTC	
MYO5C	LADC	
NCOA4	PTC, PDTC, LADC, BRCA, IC, SCT, CRC	
NUP93	NR	
PARD3	NSCLC	
PCM1	PTC, NSCLC	

PDCD10	PDTC
PICALM	LADC
PPFIBP2	PTC
PRKAR1A	NSCLC, PTC
PRKCQ	NSCLC
PRKG1	NSCLC
PRPF18	NSCLC
PTPRK	NSCLC
RABEP1	NSCLC
RABEP2	NSCLC
RASAL2	STC
RASGEF1A	BRCA
RASSF4	LADC
RBPMS	NSCLC
RIC1	NSCLC
RRBP1	CRC
RUFY2	LADC, PTC
RUFY3	MTC
SATB1	NR
SGMS1	NSCLC
SIRT1	NSCLC
SLC16A9	PTC
SNRNP70	CRC
SORBS1	NSCLC
SPECC1L	NSCLC, PTC, LPF, LPF-NT
SQSTM1	PTC
TAF3	PTC
TAS2R38	PTC
TBC1D32	LADC
TBC1D32(C6orf170)	LADC
TBL1XR1	PTC
TFG	PDTC, SCT, LPF
TIMP3	IMT
TNIP1	CRC
TRIM24	PTC, LADC, CRC
TRIM27	PTC, IC
TRIM33	PTC, LADC
TSSK4	NSCLC
VSTM4	NSCLC
WAC	NSCLC

References

- Ou, S.-H. I. and V. W. Zhu (2020). "Catalog of 5' fusion partners in RET+ NSCLC Circa 2020." *JTO Clinical and Research Reports* 1(2): 100037.
- Wang, C., Zhang, Z., Sun, Y. et al. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer. *J Transl Med* 20, 390 (2022). <https://doi.org/10.1186/s12967-022-03593-3>
- Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. *Lancet Diabetes Endocrinol.* 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9. Erratum in: *Lancet Diabetes Endocrinol.* 2021 Oct;9(10):e4. PMID: 34118198.
- Wirth, L. J., et al. (2020). "Efficacy of Selpercatinib in RET-Altered Thyroid Cancers." *383(9): 825-835.*
- Subbiah, V., Cassier, P.A., Siena, S. et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. *Nat Med* 28, 1640–1645 (2022). <https://doi.org/10.1038/s41591-022-01931-y>
- Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. *Nat Rev Clin Oncol.* 2018 Mar;15(3):151-167. doi: 10.1038/nrclinonc.2017.175. Epub 2017 Nov 14. Erratum in: *Nat Rev Clin Oncol.* 2017 Nov 28;: PMID: 29134959; PMCID: PMC7938338.
- Xiang, C., et al. (2022). "Identification and Validation of Noncanonical RET Fusions in Non-Small-Cell Lung Cancer through DNA and RNA Sequencing." *The Journal of Molecular Diagnostics* 24(4): 374-385
- Hamatani, K., et al. A novel RET rearrangement (ACBD5/RET) by pericentric inversion, inv(10)(p12.1;q11.2), in papillary thyroid cancer from an atomic bomb survivor exposed to high-dose radiation. *Oncol Rep.* 2014; 32 (5): 1809-1814
- Liu X, Hu X, Shen T, Li Q, Mooers BHM, Wu J. RET kinase alterations in targeted cancer therapy. *Cancer Drug Resist* 2020;3:472-81. <http://dx.doi.org/10.20517/cdr.2020.15>